Contract facts
UnrestrictedORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER is a federal Unrestricted award for Defense Threat Reduction Agency held by Primmune Therapeutics, Inc. Estimated value $22.5M ($11.2M obligated). Current period of performance ends Aug 31, 2026 (potential Dec 31, 2027). Last award drew 1 bidder. Place of performance: CARLSBAD CA. Related solicitation HDTRA117S0002.
ORAL BROAD SPECTRUM ANTIVIRAL TLR7 AGONIST FOR TREATMENT OF LASSA FEVER
Recompete timing
PublicCurrent PoP ended Aug 31, 2026 (27 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on HDTRA124C0014? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordPrimmune Therapeutics, Inc — $11.0M obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HDTRA124C0014?
HDTRA124C0014 (ORAL BROAD spectrum antiviral tlr7 agonist) is a Defense Threat Reduction Agency award with a potential value of $22.5M, currently held by Primmune Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HDTRA1-24-C-0014?
HDTRA1-24-C-0014 is the dashed form of PIID HDTRA124C0014 (ORAL BROAD spectrum antiviral tlr7 agonist), held by Primmune Therapeutics, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HDTRA124C0014?
Defense Threat Reduction Agency awarded HDTRA124C0014 to Primmune Therapeutics, Inc (potential $22.5M).
Who is the incumbent on HDTRA124C0014?
Primmune Therapeutics, Inc is the incumbent with $11.0M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2026.
When does Primmune Therapeutics, Inc’s HDTRA124C0014 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on HDTRA124C0014? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.